Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
The article notes that Relmada Therapeutics (RLMD) shares have fallen 29.6% over four weeks and are now technically in oversold territory, suggesting the selling pressure may have run its course.
Why it matters — RLMD watchers would care because the combination of an oversold technical condition and broad analyst agreement in raising earnings estimates could signal a potential trend reversal for the stock.